抗P185工程抗体表达与纯化的研究

人类的原癌基因Her-2编码一个185kDa的跨膜受体酪氨酸激酶,也称为p185,是肿瘤相关蛋白,在多种癌细胞,特别乳腺癌中有高表达。本实验室构建了抗p185/HER-2的二价的嵌合抗体（scFv-Fc）,并证明其保留了亲本抗体的特异结合活性,进而建立了高表达的细胞株。本研究对该嵌合抗体进行滚瓶大规模培养,并对培养产物的纯化条件进行了摸索,建立了亲和层析和阳离子交换层析两步法。最终产物的纯度达到95％以上,回收率为63％。我们还摸索了嵌合抗体的冻干保存条件,抗体可以保持其稳定性和结合活性达一年以上。嵌合抗体纯化工艺和保存条件的确定,为进一步的临床研究奠定了基础。     

rhEPO-Fc融合蛋白的表达、纯化及质量研究

用无血清培养基培养分泌表达rhEPO-Fc融合蛋白的工程细胞株MY06（CHO细胞）,收集发酵培养上清,通过离心、过滤、亲和层析、离子交换层析、分子筛等方法对目的蛋白进行纯化,通过lowry法、SDS-PAGE、Western-blot、HPLC、ELISA及IEF等方法研究目的蛋白质量,以建立rhEPO-Fc融合蛋白的发酵、纯化工艺,并探寻该融合蛋白的质量检测方法。结果通过该工艺rhEPO-Fc蛋白表达量高达2g/L,蛋白纯化得率达45%以上,纯度可达98％以上,相对分子质量约为60KD,t1/2长达38h,免疫印迹证明具有天然EPO的免疫原性。研究结果表明该生产工艺可获得rhEPO-Fc的高效表达,纯化得率高,质量检验方法稳定可靠,适用于大规模生产。     

抗人P185~(erbB2)嵌合抗体在CHO细胞中的高效表达及其活性分析

为降低人抗鼠抗体 (HAMA)反应并在CHO细胞中高效表达抗人P185 erbB2 人 /鼠嵌合抗体 ,将抗人P185 erbB2 单抗C2 5的轻、重链可变区基因分别克隆入具有人抗体恒定区基因组序列和弱化启动子驱动的选择标志基因的真核表达载体中 ,共转染CHO dhfr-细胞 ,经G418及氨甲喋呤 (MTX)梯度加压筛选进行了嵌合抗体的高效表达。采用RT PCR、ELISA、细胞ELISA、免疫荧光细胞化学等实验证实了所表达的抗人P185 erbB2 嵌合抗体的人源性及抗原特异性。培养上清中的抗体产量可达 10 0mg/L ,所表达的嵌合抗体具有抑制P185 erbB2 高表达肿瘤细胞增殖的作用     

抗人P185^erbB2嵌合抗体的CHO细胞中的高效表达及其活性分析

为降低人抗鼠抗体（HAMA）反应并在CHO细胞中高效表达抗人P185^erbB2人／鼠嵌合抗体,将抗人P185^erbB2单抗C25的轻、重链可变区基因分别克隆入具有人抗体恒定区基因组序列和弱化启动子驱地劝的选择标志基因的真核表达载体中,共转染CHO－dhfr^-细胞,经G418及氨甲喋呤（MTX）梯度加压筛选进行了嵌合抗体的高效表达,采用RT－PCR、ELISA、细胞ELISA、免疫荧光细胞化等实验证实了所表达的抗人P185^erbB2嵌合抗体的人源性及抗原特异性。培养上清中的抗体产量可达100mg/L,所表达的嵌合抗体具有抑制P185^erbB2高表达肿瘤细胞增殖的作用。     

抗ErbB2嵌合抗体chA21聚集现象的鉴定和分析

聚集现象是目前基因重组抗体面临的挑战之一.采用高效排阻色谱(HPSEC)、动态光散射(DLS)、SDS-PAGE和间接ELISA鉴定抗ErbB2嵌合抗体chA21聚集的形式和性质,并比较温度和添加剂对抗体聚集程度,抗原结合活性的影响,用圆二色谱(CD)检测不同聚集条件下蛋白构象的变化,最后将抗体酶解分离分析聚集的部位.结果表明:chA21在溶液中可形成二聚和更高形式的聚集,聚集体是通过非共价键相互作用形成,并仍保留抗原结合活性,聚集程度和活性受温度和添加剂影响,而蛋白质的构象相对稳定,抗体可变区的相互作用可能是引起聚集的主要原因之一.对抗体聚集现象的分析有助于建立稳定的抗体保存条件,并为今后抗体进一步改造提供依据.     

HSV-IgM人-鼠嵌合抗体制备及稳定细胞株构建工艺开发

为实现体外大规模制备单纯疱疹病毒HSV-IgM(HSV1,HSV2)人鼠嵌合抗体,本研究通过RNA连接酶介导的cDNA末端快速扩增(RNA ligase-mediated rapid amplification of cDNA ends,RLM-RACE)技术获取其对应杂交瘤细胞基因序列,构建嵌合抗体至真核表达载体,在CHO-S细胞中稳定表达所需目的蛋白。同时优化稳定细胞株筛选工艺,对细胞池构建阶段和单克隆筛选阶段的加压条件进行摸索与探究,最后目的抗体采用蛋白L亲和纯化法进行纯化并进行生物活性检测;最终成功制备899 kDa和909 kDa的稳定高表达重组IgM抗体(HSV1,HSV2)细胞株。结果表明,最适筛选压力为20P200M(一轮加压)和50P1000M(二轮加压);使用加压培养基进行单克隆筛选抗体表达量较高,HSV1-IgM和HSV2-IgM单克隆最终表达量分别为1620 mg/L和623 mg/L。本研究为HSV1和HSV2的IgM系列重组抗体质控品开发以及体外高表达分泌IgM亚型抗体提供理论与实践基础。     

6C6鼠-人嵌合抗体的纯化及鉴定

采用基因工程技术 ,将小鼠 6C6单克隆抗体可变区基因与人抗体恒定区基因连接 ,构建了鼠 人 6C6嵌合抗体基因 ,并在CHO细胞中高效表达 .利用ProteinA亲和层析柱从细胞培养上清中分离纯化 6C6嵌合抗体 ,得到电泳纯度大于 98%的 6C6嵌合抗体 ,其重链 (5 5kD)和轻链 (2 4kD)符合IgG相对分子质量的理论值 .Western印迹、细胞免疫荧光和免疫组织化学实验结果均呈阳性 .表明6C6嵌合抗体可识别人乳腺癌细胞表面上的肿瘤相关抗原 ,保持了 6C6单克隆抗体的特性 ,为后续的研究工作奠定了基础     

抗CD20嵌合抗体的表达与活性检测

表达了基因重组抗CD20嵌合抗体并对其生物学活性进行了初步鉴定。设计合成轻、重链可变区序列;提取血液RNA,通过RT-PCR得到人κ、IgG1的轻、重链恒定区序列。运用重叠延伸PCR,连接可变区与恒定区,将轻、重链基因连接至pIRES双表达载体。将质粒以阳离子脂质体转染CHO细胞,ELISA挑选阳性克隆,共获得7株表达较高的克隆,表达量约为2mg/L。扩大培养阳性克隆anti-CD20-1B3,收获上清,以蛋白A进行亲和层析纯化表达蛋白。SDS-PAGE检测表明纯化纯度达到95％,蛋白相对分子量与理论值吻合。以CD20₊细胞Raji、Daudi、Ramous检测,表明该抗体能与CD20抗原特异性结合,体外杀伤试验说明抗体能够杀伤CD20₊淋巴瘤细胞。     

抗H5N1病毒嵌合IgA抗体基因的构建及其在CHO细胞中的表达

为了表达具有中和活性的抗禽流感H5N1病毒人-鼠嵌合IgA抗体,采用RT-PCR法克隆具有中和活性的抗禽流感H5N1-HA鼠源单克隆抗体的轻重链可变区基因及相应的信号肽编码序列,分别与人免疫球蛋白IgA2重链恒定区、Kappa恒定区基因拼接,构建表达质粒pEF-IGHA9和pEF-IGK9,共转染二氢叶酸还原酶缺陷型CHO(CHO-dhfr-)细胞,用ELISA检测培养上清中嵌合IgA抗体的表达,对纯化的嵌合抗体进行SDS-PAGE、Western blotting印迹分析。结果成功地在CHO细胞中表达了抗禽流感H5N1病毒人-鼠嵌合IgA抗体,为制备抗H5N1重组分泌型IgA预防性抗体制剂奠定了良好的基础。     

抗体生产纯化技术

自1997年FDA批准第一个治疗淋巴癌的嵌合单抗药物Rituxan,Anti-CD-20抗体上市,并进入56个国家,至2007年,FDA已批准了20多种治疗性单抗药物,约一半用于治疗癌症,7个已成为年销售额超10亿美元的“炸弹药物”。而随着高细胞密度培养及表达技术：大规模培养的表达水平从1g/L到5g/L;细胞的培养规模越来越大从12000L到15000L和在建的20000L细胞培养规模,同时多个细胞培养罐并行运行;这些都极大地推动了大规模蛋白质纯化技术的发展：从批产几公斤到年产几十公斤抗体,发展到批生产几十公斤至年产上十吨抗体的规模。同时,新型凝胶技术、更大规模的纯化生产系统技术和膜过滤技术的发展,使经典的三步层析技术能够缩短到两步层析技术生产抗体,进一步节约了投资,提高了产能和产率。详细介绍了最新发展的两步层析主导的一条完整抗体生产纯化解决方案。     

Purification of the thermostable direct hemolysin of Vibrio parahaemolyticus by immunoaffinity column chromatography

A simple method involving immunoaffinity column chromatography to purify the thermostable direct hemolysin of Vibrio parahaemolyticus was developed. The thermostable direct hemolysin purified from the culture supernatant of a strain isolated from the first reported case of V. parahaemolyticus infection in China in 1985 was indistinguishable from the hemolysins purified from strains isolated in Japan.     

Purification of recombinant human growth hormone from CHO cell culture supernatant by Gradiflow preparative electrophoresis technology

Purification of recombinant human growth hormone (rhGH) from Chinese hamster ovary (CHO) cell culture supernatant by Gradiflow large-scale electrophoresis is described. Production of rhGH in CHO cells is an alternative to production in Escherichia coli, with the advantage that rhGH is secreted into protein-free production media, facilitating a more simple purification and avoiding resolubilization of inclusion bodies and protein refolding. As an alternative to conventional chromatography, rhGH was purified in a one-step procedure using Gradiflow technology. Clarified culture supernatant containing rhGH was passed through a Gradiflow BF200 and separations were performed over 60 min using three different buffers of varying pH. Using a 50 mM Tris/Hepes buffer at pH 7.5 together with a 50 kDa separation membrane, rhGH was purified to approximately 98% purity with a yield of 90%. This study demonstrates the ability of Gradiflow preparative electrophoresis technology to purify rhGH from mammalian cell culture supernatant in a one-step process with high purity and yield. As the Gradiflow is directly scalable, this study also illustrates the potential for the inclusion of the Gradiflow into bioprocesses for the production of clinical grade rhGH and other therapeutic proteins.     

膜渗滤亲和层析法纯化腹水单克隆抗体

用膜渗滤亲和层析法纯化腹水单克隆抗体（McAb）.采用硝酸纤维素膜（NCM）作固相支持物吸附抗原,用负压使小鼠腹水渗滤NCM,在滤过的同时腹水中的McAb不断结合于NCM上吸附的抗原,再将McAb从NCM上解离,从而得到高纯度的McAb.用此法纯化抗白蛋白（Alb）McAb.结果提纯的Alb McAb纯度达PAGE电泳单条带,将此McAb点样NCM用于斑点免疫渗滤法（DIFA）检测Alb,其灵敏度比用腹水点样时高20倍.该法快速简便,可代替亲和层析柱用于纯化McAb.     

Staphylococcal Hyaluronate Lyase: Purification and Characterization Studies

Staphylococcal hyaluronate lyase (hyaluronidase) derived from a pathogenic strain of staphylococcus was purified by means of salt fractionation with ammonium sulfate and gel filtration through Sephadex G-100. Most of the enzyme activity from concentrated culture supernatant fluids of staphylococci was obtained in a fraction precipitated by 90 to 100% saturation with ammonium sulfate. A small amount of enzyme was also precipitated by 80 to 90% saturation with the salt. The hyaluronidase-rich fractions did not contain other staphylococcal enzymes, such as coagulase, protease, lipase, and staphylokinase. These enzymes were present in the original concentrates. Molecular sieving chromatography of the partially purified enzyme by filtration through Sephadex G-100 resulted in a further increase in specific enzyme activity. However, more than one active peak was obtained after gel filtration, thus suggesting that there may be more than one molecular form of the enzyme. Immunodiffusion in agar gel of the chromatographically purified enzyme fraction, with immune serum from rabbits injected with concentrated staphylococcal culture supernatant fluids, indicated that there was one major antigen. A similar antigen, giving reactions of identity with the purified material, was present in the original culture supernatant fluid.     

Isolation of a recombinant antibody from cell culture supernatant: continuous annular versus batch and expanded-bed chromatography

Annular chromatography represents a crossflow approach to chromatographic separations, that allows the continuous separation of multicomponent mixtures. The potential of the method for continuous bioseparation has been discussed for some time, however, we demonstrate for the first time the processing of a complex feed (cell culture supernatant) taken from an actual (bio)process. Moreover, while previously published applications of annular chromatography concentrated on noninteractive (gel filtration) or nonspecific (ion exchange) chromatography, we show the possibility of continuous annular affinity chromatography. In particular, a commercially available preparative continuous annular chromatography (P-CAC) system was used to purify a recombinant antibody (human IgG(1)-kappa) from CHO cell culture supernatants by (pseudo)affinity chromatography on hydroxyapatite (HA) and rProtein A. Methods developed using small (2 mL) batch columns could be directly transferred to the P-CAC, where they yielded similar results in terms of final product quality. Yields were between 87% and 92% in the case of HA and between 77% and 82% in the case of rProtein A chromatography. DNA removal was nearly quantitative in all cases. Concomitantly, the antibody fraction of the total protein content was raised by one order of magnitude in HA and by a factor of 50 by rProtein A chromatography. In addition, a novel HA material (particle diameter -120 microm) was investigated, which was compatible with expanded-bed applications. However, the final purity of the antibody thus obtained and also the yields (<70%) were less than satisfactory.     

混合培养中巨大芽孢杆菌对氧化葡萄糖酸杆菌的作用

为查明维生素Ｃ二步发酵混合培养中巨大芽孢杆菌与氧化葡萄糖酸杆菌间的关系,通过生长曲线测定、静息细胞实验及摇瓶发酵实验研究了巨大芽孢杆菌对氧化葡萄糖酸杆菌生长和产生２－酮基－Ｌ－古龙酸作用的影响;采用超滤分离、凝胶层析及聚丙烯酰胺凝胶电泳技术对巨大芽孢杆菌胞外液中具有促进氧化葡萄糖酸杆菌产酸作用的活性物质进行了分离和纯化。结果表明,大菌胞内液和胞外液均可促进小菌生长,大菌胞外液中具有该作用的组分分子     

Induction of macrophage interleukin-1 production by Listeria monocytogenes hemolysin.

Listeriolysin O produced by a hemolytic strain of Listeria monocytogenes was purified from the ammonium sulfate precipitate of a culture supernatant through the steps of ion-exchange chromatography and gel filtration. The purified hemolysin finally gave a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with a molecular weight of 58,000. When peritoneal exudate macrophages were stimulated with purified hemolysin, we found a high level of IL-1 activity as determined by thymocyte costimulator assay in the culture supernatant. Cell-associated and intracellular IL-1 activity was also detected. The activity in the supernatant or membrane was blocked by polyclonal antibody to murine IL-1 alpha. Moreover, IL-1-specific mRNA expression could be detected in the macrophages stimulated with listeriolysin O by Northern blot analysis. Possible contamination by LPS of the listeriolysin O preparation did not seem to contribute to the induction of macrophage IL-1 production.     

sTACI-Fc-Myc重组质粒的构建、原核表达及活性鉴定

目的:构建s TACI-Fc-Myc重组质粒,并进行原核表达和纯化具有生物活性的融合蛋白。方法:通过PCR法获得s TACI-Fc-Myc重组片段,然后把融合基因片段与原核载体p ET28a连接在一起,并构建p ET28a-s TACI-Fc-Myc重组子,并转入BL21(DE3)中进行表达,用蛋白A凝胶亲和层析柱进行纯化及酶联免疫吸附剂(ELISA)法测定其生物学活性。结果:获得了s TACI-Fc-Myc重组质粒,且该质粒可以在BL21(DE3)中表达,亲和层析柱纯化后纯度可达到95%以上,与BAFF的结合活性具有剂量依赖性,浓度达到5 ng/μL时,两者的吸附达到饱和。结论:成功构建了s TACI-Fc-Myc原核表达载体,并使有生物学活性的融合蛋白在BL21(DE3)上获得了稳定表达,为进一步研究并筛选高活性BAFF拮抗肽奠定了基础。